These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Successful treatment of pure red cell aplasia because of ABO major mismatched stem cell transplant.
    Author: Sackett K, Cohn CS, Fahey-Ahrndt K, Smith AR, Johnson AD.
    Journal: J Clin Apher; 2018 Feb; 33(1):108-112. PubMed ID: 28543448.
    Abstract:
    BACKGROUND: Pure red cell aplasia (PRCA) is a well-documented potential side effect of ABO major mismatched allogeneic hematopoietic stem cell transplants. This side effect may be self-limiting, but is sometimes treated using modalities such as steroids, antithymocyte globulin, donor lymphocyte infusions, rituximab, or plasma exchanges. Another well-documented cause of pure red cell aplasia is a chronic parvovirus B19 infection, which may be seen in immunocompromised hosts. The treatment of this cause of PRCA includes removal of immunosuppression, intravenous immunoglobulin (IVIg), or rituximab; however, this condition may also be self-limiting. CASE REPORT: We show a case of a patient with PRCA who had previously received an ABO major mismatched allogeneic hematopoietic stem cell transplant, but also had an identified source of parvovirus B19 in his marrow post-transplant. RESULTS: He underwent several various treatments for his PRCA, including rituximab, bortezomib, and then plasma exchange. Anti-A IgM and IgG titers were drawn throughout his treatment course, and fell from 512 (anti-A IgM) and 1024 (anti-A IgG) to 2 (anti-A IgM) and 8 (anti-A IgG). After his last plasma exchange procedure, the patient's hemoglobin and reticulocyte count rose from 6.6 g/dL and 12.5 × 109 /L (respectively) at the onset of the PRCA diagnosis to 9.6 g/dL and 138.1 × 109 /L after a series of 14 plasma exchanges. CONCLUSION: This demonstrates a case of PRCA caused by an ABO major mismatched allogeneic hematopoietic stem cell transplant that was potentially complicated by a parvovirus infection, which was treated with multiple therapeutic interventions including a series of therapeutic plasma exchanges, rituximab, and bortezomib. Successful resolution of the patient's PRCA was achieved.
    [Abstract] [Full Text] [Related] [New Search]